Search Results

CSL Seqirus, a business of CSL (ASX: CSL), has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to fill and finish additional pre-pandemic vaccine doses as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).

https://www.cslseqirus.ca/news/news-archives/avian

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.cslseqirus.ca/news/news-archives

CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government’s outbreak and preparedness response.

https://www.cslseqirus.ca/news/news-archives/csl-seqirus-announces-us-government-award-in-response-to-avian-influenza

CSL Seqirus welcomes the federal government’s announcement highlighting the creation of a new agency, Health Emergency Readiness Canada (HERC), ensuring that Canada is prepared for future health emergencies.

https://www.cslseqirus.ca/news/news-archives/health-emergency-readiness-canada

CSL Seqirus, a global leader in seasonal influenza prevention (ASX: CSL), has shared new actionable real-world evidence (RWE) reinforcing the critical role of enhanced influenza vaccines in preventing influenza and reducing the risks of severe disease at the 10th European Scientific Working group on Influenza (ESWI) conference in Valencia.

https://www.cslseqirus.ca/news/essential-protection-for-older-adults

Recent RWE data show cell-based influenza vaccines offer 20% greater protection in the prevention of test-confirmed influenza in pediatric and adult populations relative to standard egg-based influenza vaccines

https://www.cslseqirus.ca/news/data-at-idweek-2025

CSL Seqirus is Fully Prepared to Implement the WHO’s Trivalent Influenza Vaccines Strain Selection for the 2025/26 Canadian Influenza Season

https://www.cslseqirus.ca/news/canadian-audience-only

Seqirus Ready to Reinforce Canada’s Influenza Pandemic Preparedness Plans

https://www.cslseqirus.ca/news/news-archives/seqirus-ready-to-reinforce-canadas--influenza-pandemic-preparedness-plans

FLUAD® Influenza vaccine (surface antigen, inactivated, adjuvanted with MF59® is now preferentially recommended by the Comité sur l’immunisation du Québec for adults 65 years of age and older.

https://www.cslseqirus.ca/news/news-archives/fluad-adjuvanted-flu-vaccines-for-quebec-seniors-csl-seqirus-welcomes-the-ciq-recommendation

CSL Seqirus, a business of CSL (ASX: CSL), today announced new data from five studies reinforcing the importance of seasonal influenza vaccination and exhibiting the benefits of cell-based influenza vaccines among people aged 6 months to 64 years.

https://www.cslseqirus.ca/news/idweek-2024